Insmed, Inc. (NASDAQ:INSM) Stock Has Average Price Target of $201.87

by · The Cerbat Gem

Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) have been assigned an average rating of “Buy” from the twenty-five ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $201.87.

INSM has been the subject of a number of recent research reports. Wells Fargo & Company increased their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. UBS Group restated a “buy” rating and issued a $172.00 price objective on shares of Insmed in a research note on Friday, August 7th. Evercore reaffirmed an “outperform” rating and issued a $170.00 target price on shares of Insmed in a report on Friday, August 7th. Truist Financial reaffirmed a “buy” rating and issued a $195.00 target price (up from $185.00) on shares of Insmed in a report on Monday, August 10th. Finally, Mizuho set a $192.00 target price on shares of Insmed in a research note on Tuesday, June 16th.

Check Out Our Latest Stock Report on Insmed

Insmed Price Performance

Shares of NASDAQ INSM opened at $117.83 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The stock has a 50 day moving average of $119.59 and a two-hundred day moving average of $122.13. The stock has a market cap of $25.73 billion, a P/E ratio of -28.67 and a beta of 0.82.

Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company’s revenue was up 296.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.70) earnings per share. On average, research analysts forecast that Insmed will post -1.84 earnings per share for the current year.

Insider Activity at Insmed

In other Insmed news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the sale, the chief executive officer directly owned 259,058 shares of the company’s stock, valued at $30,413,409.20. The trade was a 3.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 275,549 shares of company stock worth $36,320,872 in the last quarter. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several large investors have recently modified their holdings of INSM. Geode Capital Management LLC grew its position in Insmed by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after buying an additional 539,625 shares during the last quarter. Norges Bank acquired a new position in Insmed in the 4th quarter valued at $506,625,000. Franklin Resources Inc. raised its position in Insmed by 28.8% during the 4th quarter. Franklin Resources Inc. now owns 2,755,536 shares of the biopharmaceutical company’s stock worth $479,573,000 after buying an additional 615,811 shares during the last quarter. Bank of New York Mellon Corp raised its position in Insmed by 22.1% during the 4th quarter. Bank of New York Mellon Corp now owns 1,390,042 shares of the biopharmaceutical company’s stock worth $241,923,000 after buying an additional 251,141 shares during the last quarter. Finally, Sei Investments Co. raised its position in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock worth $228,239,000 after buying an additional 505,624 shares during the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated (NASDAQ: INSM) is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company’s work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed’s primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

Recommended Stories